Apolipoprotein C-III Inhibition and the Atherosclerosis Paradox: Lessons from the Essence-TIMI 73b Olezarsen Study

MedXY Editorial Team•Apr 9, 2026•Cardiology

Olezarsen, a novel antisense oligonucleotide targeting APOC3, demonstrated potent biochemical efficacy by reducing triglycerides by approximately 64% and remnant cholesterol by 72%.
The Essence-TIMI 73b imaging study found no significant change in the primary endpoint of non-calcified plaque volume (NCPV) at 12 months compared to placebo.
The study highlights a potential dissociation between rapid biomarker improvement (triglycerides/remnants) and immediate structural changes in coronary anatomy on a background of standard-of-care lipid therapy.
Future research must reconcile these imaging findings with long-term clinical outcome trials to determine the ultimate cardiovascular benefit of APOC3 inhibition.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Olezarsen, a novel antisense oligonucleotide targeting APOC3, demonstrated potent biochemical efficacy by reducing triglycerides by approximately 64% and remnant cholesterol by 72%.
The Essence-TIMI 73b imaging study found no significant change in the primary endpoint of non-calcified plaque volume (NCPV) at 12 months compared to placebo.
The study highlights a potential dissociation between rapid biomarker improvement (triglycerides/remnants) and immediate structural changes in coronary anatomy on a background of standard-of-care lipid therapy.
Future research must reconcile these imaging findings with long-term clinical outcome trials to determine the ultimate cardiovascular benefit of APOC3 inhibition.